Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991701 | 0.91 | LMNA (0.39) | CYP1A2CYP2C9HIF1AALDH1A1LMNA | |
| SCHEMBL2885765 | 0.86 | ALDH1A1 (0.46) | CYP1A2CYP2C9HIF1AALDH1A1LMNA | |
| SCHEMBL11233782 | 0.84 | CYP1A2 (0.42) | CYP1A2CYP2C9HIF1ACA1CA2 | |
| SCHEMBL2886933 | 0.83 | TSHR (0.47) | CYP1A2CYP2C9HIF1AALDH1A1LMNA | |
| SCHEMBL2597460 | 0.82 | CYP1A2 (0.41) | CYP1A2CYP2C9HIF1ATSHRCA1 | |
| SCHEMBL2885833 | 0.80 | HIF1A (0.44) | CYP1A2CYP2C9HIF1AALDH1A1LMNA | |
| SCHEMBL3456634 | 0.80 | DGKA (0.50) | ALDH1A1LMNAMAPTKMT2ATSHR | |
| SCHEMBL1507483 | 0.80 | DGKA (0.50) | ALDH1A1LMNAMAPTKMT2ATSHR | |
| SCHEMBL414238 | 0.80 | DGKA (0.50) | ALDH1A1LMNAMAPTKMT2ATSHR | |
| SCHEMBL3504478 | 0.78 | CYP1A2 (0.34) | CYP1A2CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040215010-A1 | Universal solid supports for solid phase oligosynthesis and methods for their preparation and use | PROLIGO, LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1289911-A2 | UNIVERSAL SOLID SUPPORTS FOR SOLID PHASE OLIGOSYNTHESIS AND METHODS FOR THEIR PREPARATION AND USE | Proligo LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096357-A2 | UNIVERSAL SOLID SUPPORTS FOR SOLID PHASE OLIGOSYNTHESIS AND METHODS FOR THEIR PREPARATION AND USE | PROLIGO LLC (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-1990003381-A1 | METHOD OF SYNTHESIS OF ALPHA OLIGORIBONUCLEOTIDES AND COMPOUNDS USEFUL FOR THE METHOD | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1990-04-05 | — | — | WO | disclosed |
| EP-0360626-A1 | Process for the synthesis of alpha-oligoribonucleotides, and components useful in the process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1990-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040215010-A1 | Universal solid supports for solid phase oligosynthesis and methods for their preparation and use | POLRMT, POLR2H, POLL | CYP1A2 4347/4885CYP2C9 2918/4885HIF1A 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.